4D Molecular Therapeutics Inc.
FDMT | NASDAQ
$15.24
+$0.02 (+0.13%)
At close: Sep 21, 2026, 4:00 PM ET
$15.17
-$0.07 (-0.46%)
After-hours:
Sep 21, 2026, 7:30 PM ET
Market Data
Market Cap $795.64M
Enterprise Value $454.99M
Beta 2.73
Average Volume 897.13K
Shares Outstanding (Diluted) 70.27M
Shares Change YoY 25.65%
Institutional Ownership 74.45%
Exchange NASDAQ
ISIN US35104E1001
Price Performance
Price Change 1M -2.8%
Price Change 3M 31.4%
Price Change 6M 54.3%
Price Change YTD 108.2%
Price Change 1Y 106.0%
Price Change 3Y 9.6%
Price Change 5Y -56.7%
1M CAGR (ann.) 44.3%
1Y CAGR (ann.) 128.5%
5Y CAGR (ann.) -14.7%
All-Time CAGR -15.6%
Valuation
PE Ratio -5.60
Forward PE N/A
PEG Ratio -0.38
Forward PEG 5.03
PS Ratio 9.03
Forward PS 43.40
PB Ratio 1.95
P/FCF Ratio -5.09
P/Adj. FCF Ratio -4.50
P/OCF Ratio -6.86
EV/Sales 5.16
EV/EBIT -3.95
EV/EBITDA -2.43
EV/FCF -2.90
Earnings Yield -17.9%
FCF Yield -19.7%
Adj. FCF Yield -22.2%
Financial Health
Net Cash $341.7M
Total Debt $19.63M
Cash & Short-Term Investments $361.33M
Total Assets $492.62M
Current Ratio 8.03
Quick Ratio 8.03
Debt / Equity Ratio 0.10
Debt / EBITDA -0.11
Debt / FCF -0.13
OCF / Debt -7.95
Interest Coverage 0.00
Altman Z-Score 3.40
Piotroski F-Score 4
Margins & Profitability
Gross Profit Margin 42.0%
Operating Profit Margin -223.4%
EBITDA Margin -200.9%
Net Profit Margin -194.7%
FCF Margin -177.6%
Adj. FCF Margin -200.7%
SBC / Revenue 22.2%
SBC Impact (per share) -13.0%
Returns
Return on Assets -36.4%
Return on Equity -41.3%
Return on Invested Capital -43.8%
Return on Capital Employed -44.3%
Return on Tangible Assets -36.4%
Historical Growth (CAGR)
Revenue CAGR 3Y 238.0%
Revenue CAGR 5Y 30.8%
Revenue CAGR 10Y N/A
EPS CAGR 3Y -6.3%
EPS CAGR 5Y 3.4%
EPS CAGR 10Y N/A
FCF CAGR 3Y -25.2%
FCF CAGR 5Y -15.7%
FCF CAGR 10Y N/A
Analyst Forecasts
Analyst Rating Buy
Analyst Count 14
EPS Growth Next 3Y -4.0%
Revenue Growth Next 3Y 29.1%
Earnings Date Nov 9, 2026
EPS Estimate (next Q) -$1.04
EPS Growth Est (next Q) 3.0%
Revenue Est (next Q) $3.46M
Revenue Growth Est (next Q) 3748.3%
Fair Value Estimates
Graham Number N/A
Graham Upside N/A
Lynch Fair Value N/A
Lynch Upside N/A
Price Target $26
Price Target Upside 70.6%
Cash Flow
Operating Cash Flow $-156.07M
Free Cash Flow $-156.67M
Adj. Free Cash Flow $-177.08M
FCF Per Share -$2.23
OCF Per Share -$2.22
OCF/S Ratio -169.6%
Income Statement
Revenue $88.23M
Gross Profit $36.95M
Operating Income $-197.12M
EBITDA $-186.96M
Net Income $-179.18M
EPS (Diluted) -$2.72
Revenue / Employee $450.14K
Profit / Employee $-914.16K
Employees 196
Add to Watchlist
Select watchlists to add or remove FDMT